Project Grant HT94252310169
Award Date
6/1/23
Completion Date
5/31/26
Dollars Obligated
$1.4M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
The Icahn School of Medicine at Mount Sinai will target the shedding of transmembrane PD-L1 to enhance therapeutic efficacy of immune checkpoint inhibitors under a $169,499 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative and impactful investigations. Specifically,...
This $507,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is supporting research at the Icahn School of Medicine at Mount Sinai (ISMMS) to study the role of exosomes in promoting prostate cancer metastasis and resistance to androgen deprivation therapy. The 2-year grant, awarded on June 15, 2024, will enable ISMMS to conduct innovative biomedical research with the goal of advancing understanding and treatment of...
The Icahn School of Medicine at Mount Sinai will receive $1,521,002 under a three-year Project Grant award from the Defense Health Agency. The grant will support research from August 1, 2023 to July 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). Specifically, the funding will enable research to determine the contribution of lineage intermediate tumor cells during progression to T-SCNC. This work aligns with the Military Medical Research and Development...
The Icahn School of Medicine at Mount Sinai will receive $760,500 from the Defense Health Agency under a three-year Project Grant award through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to functionally identify high-dimensional driver combinations in basal-like breast cancer. Through February 1, 2023 to January 31, 2026, this award will support the Icahn School of Medicine's efforts to transform health care for service members and the...
The Icahn School of Medicine at Mount Sinai has been awarded a $591,486 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, running from September 1, 2023 to August 31, 2026, will support the development of a novel immuno-oncology pipeline for FGFR2 fusion-positive cholangiocarcinoma. The funding will enable the medical school to conduct research aimed at transforming health care for service members and the...
The Icahn School of Medicine at Mount Sinai will receive $422,500 from the Department of the Army Medical Command under a two-year Project Grant award to decipher cell-cell interactions and therapeutic targets in p53-mutant adenocarcinoma at single-cell resolution. The research funded under this award, which runs from September 1, 2022 to August 31, 2024, directly supports the Military Medical Research and Development program administered by the Department of the Army Medical Command. This...
The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $2,025,908 Project Grant from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on the genetic determinants of head and neck cancer progression and immune evasion. This 4-year grant (9/1/2023 - 8/31/2027) will support computational and functional investigations aimed at improving the understanding of factors driving head and neck cancer growth and the body's immune...
The Albert Einstein College of Medicine was awarded a $1,260,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year award will support research into "A NOVEL IMMUNE CHECKPOINT PATHWAY IN HUMAN PROSTATE CANCER" from July 1, 2022 to June 30, 2025. The Military Medical Research and Development program aims to transform health care for service members and the public through innovative...
The Icahn School of Medicine at Mount Sinai received a $591,694 Project Grant award from the Department of the Army Medical Command on September 15, 2021 to complete work by September 14, 2024. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative solutions for battlefield medicine. Under this award, the Icahn School of Medicine at...
The Department of the Army Medical Command awarded a $2,028,000 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to the Icahn School of Medicine at Mount Sinai. The grant, awarded on April 1, 2025, will fund research to identify epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. The Icahn School of Medicine at Mount Sinai, a prominent academic medical center and federal grantee, will leverage its...